
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular Inc. reported a significant increase in operating income, which rose 47% year-over-year to $18.8 million, alongside a 14% organic revenue growth driven by both price and volume factors. The company achieved an adjusted gross margin of 70.4% and an adjusted operating margin of 26%, coupled with a 23% increase in adjusted EPS, reflecting strong operational efficiency and profitability. Additionally, robust regional growth, particularly in the EMEA and APAC markets, underpins a positive outlook for the company, signaling strong demand for its vascular devices and services.
Bears say
LeMaitre Vascular faces a negative outlook due to several underlying financial risks, including potential technical problems with its key mRidium pump, unexpected competition, and possible regulatory issues with the FDA, which could negatively affect its financial performance. Additionally, the company may encounter challenges related to lower price increases, competitive pressures, slower international market adoption, and reimbursement rate reductions for medical procedures, further threatening profitability. Despite international revenues exceeding expectations at $24.3 million, the risk factors combined with a reliance on revenue growth assumptions indicate a precarious financial position moving forward.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares